Camille L. Bedrosian
2019
In 2019, Camille L. Bedrosian earned a total compensation of $2.5M as Chief Medical Officer and Executive Vice President at Ultragenyx Pharmaceutical, a 48% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $230,076 |
|---|---|
| Option Awards | $863,513 |
| Salary | $511,186 |
| Stock Awards | $878,150 |
| Other | $13,891 |
| Total | $2,496,816 |
Bedrosian received $878.2K in stock awards, accounting for 35% of the total pay in 2019.
Bedrosian also received $230.1K in non-equity incentive plan, $863.5K in option awards, $511.2K in salary and $13.9K in other compensation.
Rankings
In 2019, Camille L. Bedrosian's compensation ranked 4,866th out of 13,971 executives tracked by ExecPay. In other words, Bedrosian earned more than 65.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,866 out of 13,971 | 65th |
Division Manufacturing | 1,817 out of 5,695 | 68th |
Major group Chemicals And Allied Products | 632 out of 2,194 | 71st |
Industry group Drugs | 532 out of 1,880 | 72nd |
Industry Pharmaceutical Preparations | 398 out of 1,392 | 71st |
Source: SEC filing on April 29, 2020.
Bedrosian's colleagues
We found four more compensation records of executives who worked with Camille L. Bedrosian at Ultragenyx Pharmaceutical in 2019.
2019
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
2019
John Pinion
Ultragenyx Pharmaceutical
Chief Quality Officer and Executive Vice President, Translational Sciences
2019
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
2019
Thomas Kassberg
Ultragenyx Pharmaceutical